Since both UAD and PAPP-A are non or minimally invasive and are already used in anomaly scans and first-trimester aneuploidy screening respectively, their additional utility in predicting pregnancy outcomes in women with fibroids can potentially limit maternal morbidity and be less time and cost-consuming as well. Here, PAPPA is linked to urethra adenocarcinoma.